These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16728576)

  • 1. Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf , ras and pax8 genes.
    Di Cristofaro J; Silvy M; Lanteaume A; Marcy M; Carayon P; De Micco C
    Endocr Relat Cancer; 2006 Jun; 13(2):485-95. PubMed ID: 16728576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.
    Castro P; Rebocho AP; Soares RJ; Magalhães J; Roque L; Trovisco V; Vieira de Castro I; Cardoso-de-Oliveira M; Fonseca E; Soares P; Sobrinho-Simões M
    J Clin Endocrinol Metab; 2006 Jan; 91(1):213-20. PubMed ID: 16219715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
    Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
    Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings.
    Frau DV; Lai ML; Caria P; Dettori T; Coni P; Faa G; Morandi L; Tallini G; Vanni R
    J Clin Endocrinol Metab; 2008 Jan; 93(1):177-81. PubMed ID: 17956956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laser capture microdissection is a valuable tool in the preoperative molecular screening of follicular lesions of the thyroid: an institutional experience.
    Bongiovanni M; Molinari F; Eszlinger M; Paschke R; Barizzi J; Merlo E; Giovanella L; Fasolini F; Cattaneo F; Ramelli F; Mazzucchelli L; Frattini M
    Cytopathology; 2015 Oct; 26(5):288-96. PubMed ID: 25487739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
    Albarel F; Conte-Devolx B; Oliver C
    Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
    Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
    Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules.
    Eszlinger M; Krogdahl A; Münz S; Rehfeld C; Precht Jensen EM; Ferraz C; Bösenberg E; Drieschner N; Scholz M; Hegedüs L; Paschke R
    Thyroid; 2014 Feb; 24(2):305-13. PubMed ID: 23837487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
    Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
    Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
    Nikiforova MN; Lynch RA; Biddinger PW; Alexander EK; Dorn GW; Tallini G; Kroll TG; Nikiforov YE
    J Clin Endocrinol Metab; 2003 May; 88(5):2318-26. PubMed ID: 12727991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues.
    Lacroix L; Mian C; Barrier T; Talbot M; Caillou B; Schlumberger M; Bidart JM
    Eur J Endocrinol; 2004 Sep; 151(3):367-74. PubMed ID: 15362967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
    Durante C; Puxeddu E; Ferretti E; Morisi R; Moretti S; Bruno R; Barbi F; Avenia N; Scipioni A; Verrienti A; Tosi E; Cavaliere A; Gulino A; Filetti S; Russo D
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2840-3. PubMed ID: 17488796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of PAX8/PPARG and RET/PTC rearrangements is feasible in routine air-dried fine needle aspiration smears.
    Ferraz C; Rehfeld C; Krogdahl A; Precht Jensen EM; Bösenberg E; Narz F; Hegedüs L; Paschke R; Eszlinger M
    Thyroid; 2012 Oct; 22(10):1025-30. PubMed ID: 23025542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.
    Rivera M; Ricarte-Filho J; Knauf J; Shaha A; Tuttle M; Fagin JA; Ghossein RA
    Mod Pathol; 2010 Sep; 23(9):1191-200. PubMed ID: 20526288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas.
    Marques AR; Espadinha C; Catarino AL; Moniz S; Pereira T; Sobrinho LG; Leite V
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3947-52. PubMed ID: 12161538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of thyroid tumors.
    Bhaijee F; Nikiforov YE
    Endocr Pathol; 2011 Sep; 22(3):126-33. PubMed ID: 21739166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.
    Zhu Z; Gandhi M; Nikiforova MN; Fischer AH; Nikiforov YE
    Am J Clin Pathol; 2003 Jul; 120(1):71-7. PubMed ID: 12866375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
    Banito A; Pinto AE; Espadinha C; Marques AR; Leite V
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):706-11. PubMed ID: 17651453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion.
    Foukakis T; Au AY; Wallin G; Geli J; Forsberg L; Clifton-Bligh R; Robinson BG; Lui WO; Zedenius J; Larsson C
    J Clin Endocrinol Metab; 2006 Mar; 91(3):1143-9. PubMed ID: 16352687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.